New Starts of Psychotropic Medications Dropped During COVID-19

New starts of antidepressants declined by 7.5%, anxiolytics by 5.6%, and antipsychotics by 2.6% compared with forecast levels during the first five months of the COVID-19 pandemic, according to a new study published in Health Affairs. For all medications, declines in new starts were particularly dramatic during the initial stay-at-home order period from March to May 2020. Though there was a significant rebound in new prescription starts after mid-May, the numbers remained below 2019 levels. There were substantial drops in new starts for patients younger than 18, across all medication classes, with a 34.6% decline in antidepressants, 27.3% in anxiolytics and 22.2% in antipsychotics compared with the expected levels.

© 2023 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 22

News Briefs: CDC Makes More RSV Immunizations Available to Infants

READ MORE
dna-strand
November 22

Papers Delve Into Payment Options for Gene Therapies

READ MORE
pills
November 22

A Closer Look at the Medicare Part D Landscape

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today